Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
271-285 of 474
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
Project Oncology®Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
The Future of Immunotherapy: Advancing Care in Endometrial Cancer
Project Oncology®The Future of Immunotherapy: Advancing Care in Endometrial Cancer
Casey Cosgrove, MD
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Project Oncology®CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Ryan Quigley
Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Project Oncology®Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Alexandria May, PharmD, BCPS
Angela Waanders, MD, MPH, MS
Ashley S. Margol, MD, MS
Advances in Colorectal Cancer Detection: Exploring the Role of Blood-Based Tests
GI InsightsAdvances in Colorectal Cancer Detection: Exploring the Role of Blood-Based Tests
Peter Buch, MD, FACG, AGAF, FACP
Aasma Shaukat, MD, MPH
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Ryan Quigley
- advertisement
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Project Oncology®10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Project Oncology®Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Project Oncology®Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Project Oncology®Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
Project Oncology®Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
Jennifer Caudle, DO, FACOFP
Samuel Klempner, MD
Nataliya Uboha, MD, PhD
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Project Oncology®Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Charles Turck, PharmD, BCPS, BCCCP
Luhua (Michael) Wang, MD
- advertisement
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Clinician's RoundtableAdvancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
David Feller-Kopman, MD
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Project Oncology®Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Project Oncology®Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment